Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22764123 | 0.96 | MEN1 (0.35) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL21725691 | 0.96 | MEN1 (0.35) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL22764428 | 0.96 | MEN1 (0.35) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL20334870 | 0.94 | MEN1 (0.31) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL17818782 | 0.81 | MEN1 (0.40) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL20334802 | 0.79 | MEN1 (0.34) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL9555928 | 0.79 | MEN1 (0.43) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL20841523 | 0.79 | MEN1 (0.43) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL20334661 | 0.78 | — | — | |
| SCHEMBL28769796 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562893-B2 | Benzimidazoles derivatives as Tec kinases family inhibitors | GB005, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562893-B2 | Benzimidazoles derivatives as Tec kinases family inhibitors | BMX, TEC, BTK | MEN1 2869/4885ALDH1A1 3600/4885LMNA 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.